来源
2007-5-8 9:08:59

PNAS:跨越血脑屏障 带来治疗的新革命

    血脑屏障一直是许多中枢系统疾病治疗的重要难点,许多药物都因为无法在脑内形成有效的血药浓度,从而使治疗效果大大下降。

    刚刚在本期PNAS上,以色列科学家Vivian  I.  Teichberg发现一种全新的方法,使透过血脑屏障变得简单,这一方法如何大规模应用,将开创中枢神经系统疾病治疗的革命,尤其是象蛋白质类的大分子。研究表明,在血脑屏障上有一些受体,如果某些蛋白质能很好地与这些受体结合,那么就容易被输入到中枢神经系统内。因此,以色列科学家便寻找一种能与血脑屏障上受体结合的新的治疗手段。作用使用慢病毒(lentivirus)载体系统,将溶酶体的一种酶---β-葡萄糖脑苷脂酶(β-glucocerebrosidase)和分泌状态的GFP制成融合蛋白,发现能成功在肝脏和脑中得到表达。进一步,再融合了低密度脂蛋白受体结合域到此蛋白,进一步促进了蛋白透过血脑屏障进入大脑。为此,PNAS专门为此文发表了相关的评论,高度评价了,这一治疗方法的重要意义与价值。

原始出处:

Published online before print April 26, 2007, 10.1073/pnas.0702450104
PNAS | May 1, 2007 | vol. 104 | no. 18 | 7315-7316


From the liver to the brain across the blood–brain barrier

Vivian I. Teichberg*

Department of Neurobiology, The Weizmann Institute of Science, Rehovot 76100, Israel

The burden of brain diseases as established by a recent report of the World Health Organization represents 30% of the total burden of all diseases. This surprisingly high number is clearly related to the fact that the presently available CNS drugs treat only an extremely small percentage of brain diseases, leaving untreated major disorders, such as Alzheimer's disease, brain cancer, and stroke, or minor ones, such as autism, inherited mental retardation, and ataxia. There are also relatively few CNS drugs, although not for a lack of trying. In fact, ceaseless efforts have been made by the pharmaceutical industry to develop CNS drugs, but the number of failures has unfortunately paralleled the thousands of drugs that have been designed and tested. A major stumbling block has remained the fact that very few drugs have the ability to cross the blood–brain barrier (BBB) and reach their targets within the brain parenchyma (1). The BBB is created by the endothelial cells that provide the walls of the blood vessels perfusing the brain. However, in contrast to the peripheral endothelium, the brain endothelial cells lack capillary fenestrations, display low pinocytic activity, and form very tight junctions that are highly resistant to transendothelial ionic fluxes and strictly limit the entrance of endogenous and exogenous compounds into the CNS. How to successfully negotiate the barrier has required a deep understanding of its intimate properties and a great deal of ingenuity. The paper by Spencer and Verma (2) in this issue of PNAS is a good example of the latter with some extra creativity. To fully appreciate its novelty, . . . [Full Text of this Article]

*E-mail: vivian.teichberg@weizmann.ac.il

全文链接:www.pnas.org/cgi/content/full/104/18/7315

相关报道:

警惕人和动物共患性疾病累及中枢神经系统

中枢神经系统慢病毒感染

寄生虫感染与中枢神经系统疾患

中枢神经系统影像学检查

神经系统变性疾病

德美研究人员发现诱发神经退化疾病的蛋白质

神经营养因子与退行性神经系统疾病

基因治疗可逆转动物模型的神经系统损伤

神经系统脱髓鞘疾病


  • 众说风云 (已有2条评论)

聚焦

个人基因组测序将蓬勃发展

生物谷专访:全球首家个人基因组测序机构Knome公司总裁及CEO

Master

人物

成功的秘诀

Train to gain

招聘

为你的职业拓宽道路

分子生物学相关产品



定量PCR仪

Eppendorf Ep Master
定量PCR仪

实时定量PCR仪

ABI Stepone TM 实时定量PCR仪,最新的软件系统,界面友好,操作简单

PCR产物纯化

各种厂家和各种规格的PCR产物纯化试剂盒


定量PCR试剂

最全的定量PCR试剂


荧光定量PCR全套服务方案

从引物设计到实验全程服务